콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

N1200000

Norethisterone

European Pharmacopoeia (EP) Reference Standard

동의어(들):

19-Norethindrone, 17α-Ethynyl-19-nortestosterone, 17-Hydroxy-19-nor-17α-4-pregnen-20-yn-3-one, 17α-Ethynyl-17β-hydroxy-19-nor-4-androsten-3-one, 19-Nor-17α-ethynyl-4-androsten-17β-ol-3-one, 19-Norethisterone

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C20H26O2
CAS Number:
68-22-4
Molecular Weight:
298.42
Beilstein:
1915671
MDL number:
MFCD00067596
UNSPSC 코드:
41116107
PubChem Substance ID:
329818523
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

norethisterone

제조업체/상표

EDQM

mp

205-206 °C (lit.)

응용 분야

pharmaceutical (small molecule)

형식

neat

SMILES string

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI key

VIKNJXKGJWUCNN-XGXHKTLJSA-N

유전자 정보

human ... PGR(5241)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Norethisterone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

생화학적/생리학적 작용

19-norethindrone is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases (SULT).

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

픽토그램

Health hazardEnvironment
GHS08,GHS09

신호어

Danger

유해 및 위험 성명서

H351,H360FD,H362,H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Choose from one of the most recent versions:

시험 성적서(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

이미 열람한 고객

Slide 1 of 3

1 of 3

Nandrolone British Pharmacopoeia (BP) Reference Standard

BP257

Nandrolone

Levonorgestrel European Pharmacopoeia (EP) Reference Standard

L0551000

Levonorgestrel

Mifepristone ≥98%

Sigma-Aldrich

M8046

Mifepristone

Karl van den Broeck et al.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 17(5), 321-328 (2012-09-15)
Ferdinand Peeters, a practising gynaecologist from Turnhout, near Antwerp (Belgium), had a pivotal role in the development of a practical and viable modality of oral contraception, striking the balance between efficacy and an acceptably low incidence and severity of side
Isabelle Demeestere et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(7), 903-909 (2012-11-07)
To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. Patients age 18 to 45 years were randomly assigned
V Koskela-Niska et al.
Climacteric : the journal of the International Menopause Society, 16(1), 48-53 (2012-05-30)
While previous data link the use of postmenopausal hormone therapy to an increased risk for ovarian cancer, little is known about the impact of various progestins, modes or routes of administration of hormone therapy for this risk. In this nationwide
Louise Lind Schierbeck et al.
BMJ (Clinical research ed.), 345, e6409-e6409 (2012-10-11)
To investigate the long term effect of hormone replacement therapy on cardiovascular outcomes in recently postmenopausal women. Open label, randomised controlled trial. Denmark, 1990-93. 1006 healthy women aged 45-58 who were recently postmenopausal or had perimenopausal symptoms in combination with
Patricia M LoRusso et al.
Cancer chemotherapy and pharmacology, 71(1), 193-202 (2012-10-16)
Vismodegib, a first-in-class oral hedgehog pathway inhibitor, is an effective treatment for advanced basal cell carcinoma. Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.